Dr. Kimberly Wirth received her DVM from the University of Wisconsin-Madison School of Veterinary Medicine. She also has a BS in Zoology from the University of Wisconsin-Madison.
- Intern, Southern Arizona Veterinary Specialty and Emergency Center, Tucson, AZ, 2009-2010
- Intern, Oncology Clinical Trials, University of Wisconsin-Madison School of Veterinary Medicine, Madison, WI, 2010-2011
- Resident, University of Florida College of Veterinary Medicine, Gainesville, FL, 2011-2014
On what she enjoys most about working at WVRC…“Animals positively enhance our lives, and they are able to bring out some of the best qualities in people. I realized that I wanted to care for animals, and the most logical way to do this was to become a veterinarian. Being able to offer treatment options, whether curative or palliative, for a different kind of chronic disease (cancer) is important to me. We should continue the fight against cancer while allowing patients to maintain a good quality of life.”
American College of Veterinary Internal Medicine
American Veterinary Medical Association
Veterinary Cancer Society
Dr. Wirth’s professional interests include improvement of diagnosis and treatment of canine hemangiosarcoma, osteosarcoma and metastatic lung carcinoma. She also has an interest in the ‘Fear Free’ standard of practice to alleviate fear, anxiety, and stress for pets that visit the hospital.
Research & Publications:
1. Wirth K, Kow K, Salute ME, Bacon NJ, Milner RJ. In vitro effects of Yunnan Baiyao on canine hemangiosarcoma cell lines. Vet Comp Oncol; 2016 Sep; 14(3): 281-94.
2. Kubicek L, Vanderhart D, Wirth K, An Q, Chang M, Farese J, Bova F, Sudhyadhom A, Back NJ, Milner RJ. Association between computed tomographic characteristics and fractures following stereotactic radiosurgery in dogs with appendicular osteosarcoma. Vet Radiol Ultra; 2016 May; 57(3): 321-30.
3. Speas AL, Lyles SE, Wirth KA, Fahey CE, Kow K, LeJeune AT, Milner RJ. Plasma ammonia concentration after L-asparaginase therapy in 27 dogs with high-grade lymphoma or leukemia. J Vet Emerg Crit Care; 2018 Mar; 28(2): 130-39.
4. Cerna P, Ayoob A, Baylor C, Champagne E, Hazanow S, Heidel RE, Wirth K, Legendre AM, Gunn-Moore DA. Survival analysis of 29 cats with confirmed feline infectious peritonitis (plus 74 with presumptive FIP) treated with Polyprenyl Immunostimulant that survived over 365 days. Currently in submission. 2021.
5. Cerna P, Ayoob A, Baylor C, Champagne E, Hazanow S, Heidel RE, Wirth K, Legendre AM, Gunn-Moore DA. Survival analysis of 29 cats with confirmed feline infectious peritonitis (plus 74 with presumptive FIP) treated with Polyprenyl Immunostimulant that survived over 365 days. Pathogens; 2022 Mar; 11(8): 881.